Skip to content
Triangle logo TriangleGet started
← Study library

NCT00588770 · REGISTRY CONDITION SEARCH

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-08-28

This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking blood flow to the tumor. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab in treating patients with head and neck squamous cell carcinoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Overall Response Rate

→

outcome · NOT POSTED

To Collect Blood Samples Before and After Therapy for Future Correlative Studies

→

outcome · NOT POSTED

To Collect Tumor Tissue Samples Available at Baseline From Prior Diagnostic Procedures for Future Correlative Studies

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed squamous cell cancer of the head and neck (SCCHN), from any primary site, including unknown primary cancers of the head and neck; patient must not have nasopharyngeal carcinoma of histologic types World Health Organization (WHO) 2 or 3 or squamous cell carcinoma that originated in the skin * Patients must have SCCHN that is either (a) recurrent, judged incurable by surgery or radiation or (b) metastatic; NOTE: Patients who refuse radical resection for recurrent disease are eligible; NOTE: A second primary squamous cell carcinoma of the head and neck is allowed if eligibility is based on a recurrent or metastatic first primary squamous cell carcinoma of the head and neck * No prior chemotherapy or biologic/molecular targeted therapy for recurrent or metastatic SCCHN * Patients may have received one regimen of induction, concomitant chemoradiotherapy and/or adjuvant chemotherapy as part of initial potential curative therapy but must not have received prior chemotherapy for recurrent or metastatic disease * A minimum of 4 months is required between last dose of chemotherapy or chemoradiotherapy and study treatment; in addition patients must be progression-free for at least 4 months after completion of chemotherapy or chemoradiotherapy or radiation plus cetuximab given with a curative intent; (cetuximab therapy: 4 months is required between last dose of chemotherapy or chemoradiotherapy and study treatment if part of concurrent regimen, 8 weeks if part of adjuvant regimen post radiation) * Patients having progression after 2 cycles of induction chemotherapy are not eligible for the study * No prior bevacizumab is allowed * A maximum of one prior radiotherapy regimen, curative or palliative, to the head and neck is allowed; if the radiation is combined with chemotherapy and/or cetuximab, a minimum of 4 months must elapse between the end of radiotherapy and registration; if the radiation is given alone, a minimum of 8 weeks must elapse between the end of radiotherapy and registration; a minimum of 3 weeks must elapse between prior radiation to other areas and registration * Patients must not be receiving any other investigational agent while on the study * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patients must have recovered to grade 1 or better from any acute effects of prior surgery, chemotherapy, or radiation therapy, and should be \> 4 weeks post surgery; chronic late xerostomia, speech and swallowing abnormalities resulting from prior radiation or surgery are permitted if nutritional status is stable * Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST); baseline measurements and evaluations of all sites of disease must be obtained =\< 4 weeks prior to randomization; disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapy; persistent disease after radiotherapy must be biopsy proven at least 8 weeks after completion of radiation therapy; (radiographic findings are acceptable providing that clear-cut measurements can be made) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Hemoglobin (Hgb) \>= 8.0 g/dL * Platelet count \>= 100,000/mm\^3 * Creatinine clearance of \>= 60 ml/min; creatinine clearance may be measured or calculated; if calculating, creatinine clearance, use the Cockroft-Gault formula * Total bilirubin within normal limits (must be obtained =\< 2 weeks prior to randomization) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility * Alkaline phosphatase normal AND AST or ALT =\< 5 x upper limit of normal (ULN) * Alkaline phosphatase \> 1 but =\< 2.5 x ULN AND AST or ALT \> 1 but =\< 1.5 x ULN * Alkaline phosphatase \> 2.5 but =\< 5 x ULN AND AST or ALT normal * Alkaline phosphatase must be within the range allowing for eligibility * Urine dipstick must be =\< 0-1+ within 2 weeks (14 days) of randomization; if urine dipstick result is \> 1+, a calculation of urine protein creatinine (UPC) ratio is required; patients must have a UPC ratio \< 1.0 to participate in the study; NOTE: UPC ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm * No known brain metastases * Patients who meet the following criteria will be excluded: * Tumors that invade major vessels (e.g. the carotid) as shown unequivocally by imaging studies * Central (i.e. within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies * Any prior history of bleeding related to the current head and neck cancer * History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) =\< 3 months prior to enrollment * No history of coagulopathy or hemorrhagic disorders * Patients should not have a history of thrombosis (e.g. pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of warfarin 1 mg per day is allowed) and international normalized ratio (INR) should be \< 1.5 at registration * Patients must not be receiving chronic daily treatment with aspirin (\> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function; the use of anti-platelet agents (e.g. dipyridamole \[Persantine\], ticlopidine \[Ticlid\], clopidogrel \[Plavix\]) is allowed only if patient is not receiving aspirin or NSAID's known to inhibit platelet function * No hypercalcemia related to head and neck cancer * Patients with a prior history of squamous cell or basal carcinoma of the skin or in situ cervical cancer must have been curatively treated; patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post diagnosis * No current peripheral neuropathy \>= grade 2 at time of randomization * Patients must not have any co-existing condition that would preclude full compliance with the study * No prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80, if the physician's choice of chemotherapy regimen is docetaxel * All patients must have blood pressure =\< 150/90 =\< 2 weeks prior to randomization; patients with history of hypertension must be well-controlled upon study entry (=\< 150/90) on a stable regimen of anti-hypertensive therapy * No major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study * No unstable angina or myocardial infarction within the previous 6 months; no symptomatic congestive heart failure, New York Heart Association (NYHA) grade II or greater; no history of aortic dissection or presence of aneurysm \> 6 cm (or at high risk for rupture); no serious cardiac arrhythmia requiring medication (history of chronic atrial fibrillation or other atrial arrhythmia with controlled rate on medication is allowed); no clinically significant peripheral vascular disease manifested by intermittent claudication or need for vascular intervention; no history of aortic dissection; no history of any central nervous system (CNS) cerebrovascular ischemia or stroke within the last 6 months; no active serious infection * Patients should not have prior history of a serious human anti-human antibody (HAHA) reaction; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible * Women must not be pregnant or breast feeding; pregnant women are excluded from this study; women of child-bearing potential and men must agree to total abstinence or to use adequate hormonal or barrier method of birth control prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while in this study, she should inform her treating physician immediately; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy * Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated * No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Docetaxel
    3. Other: Laboratory Biomarker Analysis
    label
    Arm IA (docetaxel, cisplatin)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
    intervention Names
    1. Biological: Bevacizumab
    2. Drug: Cisplatin
    3. Drug: Docetaxel
    4. Other: Laboratory Biomarker Analysis
    label
    Arm IB (docetaxel, cisplatin, bevacizumab)
    type
    EXPERIMENTAL
  3. description
    Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Carboplatin
    2. Drug: Docetaxel
    3. Other: Laboratory Biomarker Analysis
    label
    Arm IIA (docetaxel, carboplatin)
    type
    ACTIVE_COMPARATOR
  4. description
    Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
    intervention Names
    1. Biological: Bevacizumab
    2. Drug: Carboplatin
    3. Drug: Docetaxel
    4. Other: Laboratory Biomarker Analysis
    label
    Arm IIB (docetaxel, carboplatin, bevacizumab)
    type
    EXPERIMENTAL
  5. description
    Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Fluorouracil
    3. Other: Laboratory Biomarker Analysis
    label
    Arm IIIA (cisplatin, fluorouracil)
    type
    ACTIVE_COMPARATOR
  6. description
    Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
    intervention Names
    1. Biological: Bevacizumab
    2. Drug: Cisplatin
    3. Drug: Fluorouracil
    4. Other: Laboratory Biomarker Analysis
    label
    Arm IIIB (cisplatin, fluorouracil, bevacizumab)
    type
    EXPERIMENTAL
  7. description
    Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Carboplatin
    2. Drug: Fluorouracil
    3. Other: Laboratory Biomarker Analysis
    label
    Arm IVA (carboplatin, fluorouracil)
    type
    ACTIVE_COMPARATOR
  8. description
    Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
    intervention Names
    1. Biological: Bevacizumab
    2. Drug: Carboplatin
    3. Drug: Fluorouracil
    4. Other: Laboratory Biomarker Analysis
    label
    Arm IVB (carboplatin, fluorouracil, bevacizumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm IB (docetaxel, cisplatin, bevacizumab)
    2. Arm IIB (docetaxel, carboplatin, bevacizumab)
    3. Arm IIIB (cisplatin, fluorouracil, bevacizumab)
    4. Arm IVB (carboplatin, fluorouracil, bevacizumab)
    description
    Given IV
    name
    Bevacizumab
    other Names
    1. ABP 215
    2. ABP-215
    3. ABP215
    4. Alymsys
    5. Anti-VEGF
    6. Anti-VEGF Humanized Monoclonal Antibody
    7. Anti-VEGF Monoclonal Antibody SIBP04
    8. Anti-VEGF rhuMAb
    9. Avastin
    10. Avegra
    11. Avzivi
    12. Aybintio
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Arm IIA (docetaxel, carboplatin)
    2. Arm IIB (docetaxel, carboplatin, bevacizumab)
    3. Arm IVA (carboplatin, fluorouracil)
    4. Arm IVB (carboplatin, fluorouracil, bevacizumab)
    description
    Given IV
    name
    Carboplatin
    other Names
    1. Blastocarb
    2. Carboplat
    3. Carboplatin Hexal
    4. Carboplatino
    5. Carboplatinum
    6. Carbosin
    7. Carbosol
    8. Carbotec
    9. CBDCA
    10. Displata
    11. Ercar
    12. JM-8
    type
    DRUG
  3. arm Group Labels
    1. Arm IA (docetaxel, cisplatin)
    2. Arm IB (docetaxel, cisplatin, bevacizumab)
    3. Arm IIIA (cisplatin, fluorouracil)
    4. Arm IIIB (cisplatin, fluorouracil, bevacizumab)
    description
    Given IV
    name
    Cisplatin
    other Names
    1. Abiplatin
    2. Blastolem
    3. Briplatin
    4. CDDP
    5. Cis-diammine-dichloroplatinum
    6. Cis-diamminedichloridoplatinum
    7. Cis-diamminedichloro Platinum (II)
    8. Cis-diamminedichloroplatinum
    9. Cis-dichloroammine Platinum (II)
    10. Cis-platinous Diamine Dichloride
    11. Cis-platinum
    12. Cis-platinum II
    type
    DRUG
  4. arm Group Labels
    1. Arm IA (docetaxel, cisplatin)
    2. Arm IB (docetaxel, cisplatin, bevacizumab)
    3. Arm IIA (docetaxel, carboplatin)
    4. Arm IIB (docetaxel, carboplatin, bevacizumab)
    description
    Given IV
    name
    Docetaxel
    other Names
    1. Docecad
    2. RP 56976
    3. RP-56976
    4. RP56976
    5. Taxotere
    6. Taxotere Injection Concentrate
    type
    DRUG
  5. arm Group Labels
    1. Arm IIIA (cisplatin, fluorouracil)
    2. Arm IIIB (cisplatin, fluorouracil, bevacizumab)
    3. Arm IVA (carboplatin, fluorouracil)
    4. Arm IVB (carboplatin, fluorouracil, bevacizumab)
    description
    Given IV
    name
    Fluorouracil
    other Names
    1. 5 Fluorouracil
    2. 5 Fluorouracilum
    3. 5 FU
    4. 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
    5. 5-Fluorouracil
    6. 5-Fluracil
    7. 5-Fu
    8. 5FU
    9. AccuSite
    10. Carac
    11. Fluoro Uracil
    12. Fluouracil
    type
    DRUG
  6. arm Group Labels
    1. Arm IA (docetaxel, cisplatin)
    2. Arm IB (docetaxel, cisplatin, bevacizumab)
    3. Arm IIA (docetaxel, carboplatin)
    4. Arm IIB (docetaxel, carboplatin, bevacizumab)
    5. Arm IIIA (cisplatin, fluorouracil)
    6. Arm IIIB (cisplatin, fluorouracil, bevacizumab)
    7. Arm IVA (carboplatin, fluorouracil)
    8. Arm IVB (carboplatin, fluorouracil, bevacizumab)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
403
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    These were blood and tissue samples collections and have no data to report.
    measure
    To Collect Blood Samples Before and After Therapy for Future Correlative Studies
    time Frame
    Before and after therapy
  2. description
    These were blood and tissue samples collections and have no data to report.
    measure
    To Collect Tumor Tissue Samples Available at Baseline From Prior Diagnostic Procedures for Future Correlative Studies
    time Frame
    Baseline
primary Outcomes
  1. description
    Overall survival (OS) was defined as time from randomization to death from any course. Patients who were alive were censored at the last contact date. Median OS was estimated using the Kaplan-Meier method.
    measure
    Overall Survival (OS)
    time Frame
    assessed every 3 months within 2 years from study entry, then every 6 months up to 5 years from study entry
secondary Outcomes
  1. description
    Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression-free survival (PFS) was defined as the time from randomization to date of disease progression or death from any cause, whichever occurred first. Patients who were still alive and progression free were censored at last disease assessment date. Median PFS was estimated using Kaplan-Meier method.
    measure
    Progression-free Survival (PFS)
    time Frame
    on both arms, assessed every 2 cycles during chemotherapy treatment, then assessed every 9 weeks until progression up to 5 years from study entry; patients on arm B were assessed every 2 cycles for additional 12 weeks before changing to every 9 weeks
  2. description
    Overall response rate is defined as number of patients with complete response (CR) or partial response (PR) divided by all patients. Responses are evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline. CR is defined as disappearance of all target and non-target lesions. PR is defined as disappearance of target lesions or at least a 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameters), and persistence of one or more non-target lesion(s).
    measure
    Overall Response Rate
    time Frame
    on both arms, assessed every 2 cycles during chemotherapy treatment, then assessed every 9 weeks until progression up to 5 years from study entry; patients on arm B were assessed every 2 cycles for additional 12 weeks before changing to every 9 weeks
Full study description
brief Summary
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking blood flow to the tumor. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab in treating patients with head and neck squamous cell carcinoma.
detailed Description
PRIMARY OBJECTIVES: I. To compare the overall survival of patients with recurrent or metastatic head and neck cancer treated with standard platinum-based chemotherapy with or without bevacizumab. SECONDARY OBJECTIVES: I. To assess toxicities with the addition of bevacizumab to each platinum-doublet (cisplatin/docetaxel, carboplatin/docetaxel, cisplatin/fluorouracil \[5-FU\], carboplatin/5-FU). II. To compare the objective response rates and the progression-free survival achieved with the above therapies. III. To collect blood samples before and after therapy for future correlative studies. IV. To collect tumor tissue samples available at baseline from prior diagnostic procedures for future correlative studies. OUTLINE: After the physician decides which chemotherapy doublet to use, patients are randomized to 1 of 2 treatment arms for that chemotherapy combination. ARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA. ARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm IIA. ARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA. ARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Source references
references
  1. citation
    Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. J Clin Oncol. 2019 Dec 1;37(34):3266-3274. doi: 10.1200/JCO.19.00555. Epub 2019 Oct 16.
    pmid
    31618129
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5e24ab74a66241864de7
      requested nct id
      NCT00588770
      primary nct id
      NCT00588770
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      08cd5e25e3443192e3c8852dc8720f59a5a4ec1ab6dabef4f86115994540f421
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5e24ab74a66241864de7
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00588770
      occurrences
      1. context exact
        NCT00588770
        end
        11
        exact text
        NCT00588770
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/107/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c932d84bab876b646901bbc48fa4a6f1975282a95175d27bba144ab0a43455fb
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-61753ba92ba28f3b3cf3
      requested nct id
      NCT00588770
      primary nct id
      NCT00588770
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      payload sha256
      8689ba6b5d2d61cf10af07323fa8a0518c0aa4a89ba74a2a2d1e11369d224445
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-61753ba92ba28f3b3cf3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00588770
      occurrences
      1. context exact
        NCT00588770
        end
        11
        exact text
        NCT00588770
        start
        0
      offset unit
      unicode_code_points
      query cond
      Salivary Gland Cancer
      query disease state id
      ds-salivary-gland-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      source json pointer
      /studies/45/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c932d84bab876b646901bbc48fa4a6f1975282a95175d27bba144ab0a43455fb
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a882b8b391716ff5da4b
      requested nct id
      NCT00588770
      primary nct id
      NCT00588770
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      67accbfb21c58f62b0c9d0b731efa642f2423a24c2c6442ffc9ce31150089425
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a882b8b391716ff5da4b
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00588770
      occurrences
      1. context exact
        NCT00588770
        end
        11
        exact text
        NCT00588770
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/80/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      c932d84bab876b646901bbc48fa4a6f1975282a95175d27bba144ab0a43455fb

    Preserved source evidence · Not medical advice